NCT04689412

Brief Summary

As most of the upper airways infections (UAI) leading to wheezing are secondary to viral triggers, the possible antinflammatory and antiviral role of resveratrol has been suggested in several studies, both in vitro and in vivo. However, its efficacy has been studied only when evaluating upper respiratory symptoms. With the aim to define new approaches in patients with recurrent wheezing triggered by UAI we have performed a prospective observational study to evaluate the efficacy of a short-course of intranasal resveratrol, administered for 7 days at the beginning of UAI, when compared to standard nasal lavage with 0.9% saline solution, in terms of reduction in wheezing episodes.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Apr 2018

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2018

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 31, 2019

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

April 30, 2019

Completed
1.7 years until next milestone

First Submitted

Initial submission to the registry

December 27, 2020

Completed
3 days until next milestone

First Posted

Study publicly available on registry

December 30, 2020

Completed
Last Updated

December 30, 2020

Status Verified

December 1, 2020

Enrollment Period

12 months

First QC Date

December 27, 2020

Last Update Submit

December 27, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Wheezing days

    number of wheezing days during the follow-up period

    october 2017 - march 2018

Secondary Outcomes (2)

  • Severity index

    october 2017 - march 2018

  • Severity index

    october 2017 - march 2018

Study Arms (2)

Cases

Children spontaneously treated with nasal resveratrol at the beginning of each upper airways infection

Drug: Resveratrol

Controls

Children spontaneously treated with nasal lavage at the beginning of each upper airways infection

Interventions

Nasal administration of resveratrol

Cases

Eligibility Criteria

Age3 Years - 5 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)
Sampling MethodProbability Sample
Study Population

Patients were selected from those referring to our centre for recurrent wheezing in the previous year.

You may qualify if:

  • Presence of at least 8 episodes of wheezing in the previous October-March period
  • Negative skin prick test (SPT) for the most common allergens.
  • Age less than 6 years

You may not qualify if:

  • Sensitization to food allergens
  • Sensitization to perennial allergens or to tree pollen allergens.
  • Presence of atopic dermatitis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Università di Perugia

Perugia, 06100, Italy

Location

MeSH Terms

Conditions

Respiratory SoundsRespiratory Tract Infections

Interventions

Resveratrol

Condition Hierarchy (Ancestors)

Signs and Symptoms, RespiratorySigns and SymptomsPathological Conditions, Signs and SymptomsInfectionsRespiratory Tract Diseases

Intervention Hierarchy (Ancestors)

StilbestrolsStilbenesBenzylidene CompoundsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsOrganic ChemicalsPolyphenolsPhenols

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Prof. Giuseppe Di Cara

Study Record Dates

First Submitted

December 27, 2020

First Posted

December 30, 2020

Study Start

April 1, 2018

Primary Completion

March 31, 2019

Study Completion

April 30, 2019

Last Updated

December 30, 2020

Record last verified: 2020-12

Data Sharing

IPD Sharing
Will not share

Locations